MA43168A - Dérivés de n-[2-(1-benzylpipéridin-4-yl)éthyl]-4-(pyrazin-2-yl)-pipérazine-1-carboxamide et composés apparentés en tant qu'antagonistes du récepteur muscarinique 4 (m4) pour le traitement de maladies neurologiques - Google Patents

Dérivés de n-[2-(1-benzylpipéridin-4-yl)éthyl]-4-(pyrazin-2-yl)-pipérazine-1-carboxamide et composés apparentés en tant qu'antagonistes du récepteur muscarinique 4 (m4) pour le traitement de maladies neurologiques

Info

Publication number
MA43168A
MA43168A MA043168A MA43168A MA43168A MA 43168 A MA43168 A MA 43168A MA 043168 A MA043168 A MA 043168A MA 43168 A MA43168 A MA 43168A MA 43168 A MA43168 A MA 43168A
Authority
MA
Morocco
Prior art keywords
carboxamide
benzylpiperidin
pyrazin
piperazine
antagonists
Prior art date
Application number
MA043168A
Other languages
English (en)
Inventor
Nicole Harriott
Nicholas Pagano
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of MA43168A publication Critical patent/MA43168A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
MA043168A 2015-11-06 2016-11-04 Dérivés de n-[2-(1-benzylpipéridin-4-yl)éthyl]-4-(pyrazin-2-yl)-pipérazine-1-carboxamide et composés apparentés en tant qu'antagonistes du récepteur muscarinique 4 (m4) pour le traitement de maladies neurologiques MA43168A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562252179P 2015-11-06 2015-11-06
US201662275708P 2016-01-06 2016-01-06

Publications (1)

Publication Number Publication Date
MA43168A true MA43168A (fr) 2018-09-12

Family

ID=57349137

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043168A MA43168A (fr) 2015-11-06 2016-11-04 Dérivés de n-[2-(1-benzylpipéridin-4-yl)éthyl]-4-(pyrazin-2-yl)-pipérazine-1-carboxamide et composés apparentés en tant qu'antagonistes du récepteur muscarinique 4 (m4) pour le traitement de maladies neurologiques

Country Status (22)

Country Link
US (2) US11033539B2 (fr)
EP (1) EP3371164B1 (fr)
JP (2) JP6917989B2 (fr)
KR (1) KR20180073685A (fr)
CN (1) CN108349936B (fr)
AU (1) AU2016348524B2 (fr)
BR (1) BR112018008630A2 (fr)
CA (1) CA3001873A1 (fr)
CL (1) CL2018001217A1 (fr)
CO (1) CO2018004800A2 (fr)
ES (1) ES2915266T3 (fr)
HK (1) HK1253029A1 (fr)
IL (1) IL258862B (fr)
MA (1) MA43168A (fr)
MX (1) MX386148B (fr)
MY (1) MY194461A (fr)
PE (1) PE20181010A1 (fr)
PH (1) PH12018500940A1 (fr)
SA (1) SA518391518B1 (fr)
SG (1) SG11201803757UA (fr)
TN (1) TN2018000130A1 (fr)
WO (1) WO2017079641A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA122589C2 (uk) 2015-11-06 2020-12-10 Ф. Хоффманн-Ля Рош Аг Похідні індолін-2-ону
TN2018000130A1 (en) * 2015-11-06 2019-10-04 Neurocrine Biosciences Inc N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
CA3072081A1 (fr) 2017-08-08 2019-02-14 Vanderbilt University Antagonistes du recepteur muscarinique de l'acetylcholine m4
CA3079188A1 (fr) 2017-10-17 2019-04-25 Vanderbilt University Antagonistes du recepteur muscarinique de l'acetylcholine m4
US11299481B2 (en) 2017-10-20 2022-04-12 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
EP3703680B1 (fr) 2017-10-31 2024-05-15 Vanderbilt University Antagonistes du récepteur muscarinique m4 à l'acétylcholine
EP3732163A4 (fr) 2017-12-20 2021-07-14 Vanderbilt University Antagonistes du récepteur muscarinique de l'acétylcholine m4
JP7352294B2 (ja) * 2018-02-02 2023-09-28 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
TWI903299B (zh) 2018-03-08 2025-11-01 美商英塞特公司 作為PI3K-γ抑制劑之胺基吡嗪二醇化合物
WO2020010003A1 (fr) 2018-07-02 2020-01-09 Incyte Corporation DÉRIVÉS D'AMINOPYRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE PI3K-γ
WO2020048826A1 (fr) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft Composés de la 1-oxa-3,9-diazaspiro[5.5]undécan-2-one substituée en position 5
WO2020048827A1 (fr) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft Composés de la 1,3,9-triazaspiro[5.5]undécan-2-one
WO2020048828A1 (fr) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft Composés du 5-hétéroaryl-3,9-diazaspiro[5.5]undécane
EP3846806A4 (fr) 2018-09-04 2022-06-08 Pipeline Therapeutics, Inc. Antagonistes du récepteur m1 de l'acétylcholine muscarinique
CN119241444A (zh) * 2019-06-17 2025-01-03 德西费拉制药有限责任公司 氨基嘧啶酰胺自噬抑制剂及其使用方法
WO2021055630A1 (fr) * 2019-09-17 2021-03-25 Bial- Biotech Investments, Inc. Carboxamides n-hétérocycliques substitués, saturés et insaturés et composés apparentés pour leur utilisation dans le traitement de troubles médicaux
CN121378271A (zh) 2019-10-07 2026-01-23 康蒂内乌姆医疗公司 毒蕈碱型乙酰胆碱m1受体拮抗剂
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
WO2021113478A1 (fr) 2019-12-06 2021-06-10 Neurocrine Biosciences, Inc. Antagonistes du récepteur muscarinique 4 et procédés d'utilisation
CN111072551A (zh) * 2019-12-30 2020-04-28 上海睿瓦科技有限公司 催化氢化一步法制取哌啶胺的方法
AR121260A1 (es) * 2020-02-05 2022-05-04 Neurocrine Biosciences Inc Antagonistas del receptor muscarínico 4 y métodos de uso
WO2022156708A1 (fr) * 2021-01-20 2022-07-28 Jacobio Pharmaceuticals Co., Ltd. Inhibiteur d'enzyme parp7
WO2022261404A1 (fr) * 2021-06-11 2022-12-15 Neuronascent, Inc. Méthodes et compositions pour formulation lipidique de thérapies à petites molécules lipophiles du type hétérocyclique
WO2023010078A1 (fr) * 2021-07-30 2023-02-02 Neurocrine Biosciences, Inc. Antagonistes du récepteur muscarinique 4 et méthodes d'utilisation
AU2023382489A1 (en) * 2022-11-16 2025-06-05 Vyrnwy Therapeutics, Inc. Inhibitors of tyk2

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07502529A (ja) * 1991-12-31 1995-03-16 藤沢薬品工業株式会社 アセチルコリンエステラーゼ阻害およびムスカリン様のアゴニスト活性を有するオキサジアゾール誘導体
GB9313201D0 (en) * 1993-06-25 1993-08-11 Fujisawa Pharmaceutical Co New heterocyclic compounds
US5700801A (en) * 1994-12-23 1997-12-23 Karl Thomae, Gmbh Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
EP1553085A1 (fr) * 1997-11-18 2005-07-13 Teijin Limited Dérivés d'amines cycliques et leur utilisation comme medicament
DE60023878T2 (de) * 1999-05-18 2006-07-20 Teijin Ltd. Heilmittel und vorbeugung für mit chemokinen verbundenen erkrankungen
CA2384018C (fr) 1999-09-22 2010-01-12 Schering Corporation Antagonistes muscariniques
CA2393757C (fr) * 1999-12-08 2009-04-07 Teijin Limited Antagonistes du recepteur ccr5 de la cycloamine
US6362177B1 (en) * 2000-05-16 2002-03-26 Teijin Limited Cyclic amine derivatives and their use as drugs
WO2003062234A1 (fr) * 2002-01-23 2003-07-31 Yamanouchi Pharmaceutical Co., Ltd. Composes de quinoxaline
US8673924B2 (en) * 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
AU2003300902A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Piperidine derivatives as CCR5 antagonists
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
EP1904446A2 (fr) * 2005-07-11 2008-04-02 Ranbaxy Laboratories Limited Antagonistes des recepteurs muscariniques
KR20080087833A (ko) * 2005-12-21 2008-10-01 쉐링 코포레이션 히스타민 ｈ３ 길항제로서 유용한 페녹시피페리딘 및 이의유사체
WO2007130383A2 (fr) * 2006-04-28 2007-11-15 Northwestern University Compositions et traitements utilisant des pyridazines et des secrétases
EP1997805A1 (fr) * 2007-06-01 2008-12-03 Commissariat à l'Energie Atomique Compositions à activité antiparasite, applications associées au traitement des maladies infectieuses causées par des apicomplexans
JP2013028538A (ja) * 2009-11-13 2013-02-07 Dainippon Sumitomo Pharma Co Ltd 新規アミド誘導体
MX2014006015A (es) 2011-11-25 2014-06-04 Nerviano Medical Sciences Srl Derivados de 3-fenil-isoquinolin-1 (2h) -ona como inhibidores de parp-1.
WO2014074517A1 (fr) * 2012-11-08 2014-05-15 Emory University Compositions cellulaires utilisées pour la restauration de la fonction de cellules souches ou de cellules progénitrices et procédés associés
BR112015011094A2 (pt) * 2012-11-20 2017-07-11 Hoffmann La Roche 1,6-naftiridinas substituídas
SG11201506385WA (en) * 2013-03-18 2015-10-29 Genoscience Pharma Quinolines derivatives as novel anticancer agents
EP2982666B1 (fr) * 2013-04-04 2019-08-07 Takeda Pharmaceutical Company Limited Composé hétérocyclique
US9611223B2 (en) * 2013-09-11 2017-04-04 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
EP3119393A4 (fr) * 2014-03-20 2018-02-28 Samumed, LLC Indazole-3-carboxamides 5-substitués, et préparation et utilisation de ceux-ci
TN2018000130A1 (en) * 2015-11-06 2019-10-04 Neurocrine Biosciences Inc N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases

Also Published As

Publication number Publication date
MX2018005215A (es) 2018-08-01
PH12018500940A1 (en) 2018-12-17
US20180325887A1 (en) 2018-11-15
PE20181010A1 (es) 2018-06-26
AU2016348524B2 (en) 2021-01-28
JP2021050243A (ja) 2021-04-01
CO2018004800A2 (es) 2018-10-31
TN2018000130A1 (en) 2019-10-04
IL258862B (en) 2021-02-28
CL2018001217A1 (es) 2018-08-03
SA518391518B1 (ar) 2021-06-13
ES2915266T3 (es) 2022-06-21
WO2017079641A1 (fr) 2017-05-11
CN108349936A (zh) 2018-07-31
MX386148B (es) 2025-03-18
HK1253029A1 (zh) 2019-06-06
IL258862A (en) 2018-06-28
CN108349936B (zh) 2021-10-01
MY194461A (en) 2022-11-30
KR20180073685A (ko) 2018-07-02
JP6917989B2 (ja) 2021-08-11
EP3371164A1 (fr) 2018-09-12
CA3001873A1 (fr) 2017-05-11
US11033539B2 (en) 2021-06-15
EP3371164B1 (fr) 2022-03-16
AU2016348524A1 (en) 2018-05-17
US20210338653A1 (en) 2021-11-04
BR112018008630A2 (pt) 2018-10-30
JP2018531981A (ja) 2018-11-01
SG11201803757UA (en) 2018-06-28

Similar Documents

Publication Publication Date Title
MA43168A (fr) Dérivés de n-[2-(1-benzylpipéridin-4-yl)éthyl]-4-(pyrazin-2-yl)-pipérazine-1-carboxamide et composés apparentés en tant qu'antagonistes du récepteur muscarinique 4 (m4) pour le traitement de maladies neurologiques
EP3411380A4 (fr) Composés destinés au traitement de troubles ou de maladies oculaires
MA55325A (fr) Composés pour le traitement de maladies pd-l1
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
MA41841A (fr) Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
MA54229A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
EP3347368A4 (fr) Composés et formulations pour traiter les maladies ophthalmiques
EP3704108A4 (fr) Composés et compositions pour le traitement de troubles hématologiques
EP3463315A4 (fr) Compositions et méthodes d'utilisation de nintédanib pour le traitement de maladies oculaires à néovascularisation anormale
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP4045036A4 (fr) Amides hétéroaryle-biphényle pour le traitement de maladies associées à pd-l1
ME03314B (fr) Thérapie basée sur l'arnm pour le traitement des maladies oculaires
EP3352749A4 (fr) Composés et compositions pour le traitement de troubles oculaires
IL281809A (en) Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
EP3496715A4 (fr) Composés utiles pour modifier les taux d'acides biliaires pour le traitement du diabète et de maladies cardiométaboliques.
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
EP3749322A4 (fr) Composés et méthodes de traitement d'une dépendance et de troubles associés
EP3877383A4 (fr) Composés et compositions pour le traitement de maladies respiratoires
EP3352755A4 (fr) Nouveaux composés, compositions et méthodes pour le traitement de troubles cutanés
MA50069A (fr) Dérivés 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-méthylpropan-2-ol et composés similaires en tant qu'inhibiterus il-7 et ifn-gamma pour le traitement de maladies autoimmune et inflammation chronique
EP4050997A4 (fr) Traitement de maladies oculaires à l'aide d'antagonistes du récepteur de l'endothéline
MA49140A (fr) Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques
EP3593803A4 (fr) Composés destinés au traitement de maladies causées par l'accumulation d'oxalate
EP3373931A4 (fr) Composés hétérocycliques pour le traitement de maladies